Navigation Links
Spectros Signs New International Distribution Deals
Date:10/19/2009

PORTOLA VALLEY, Calif., Oct. 19 /PRNewswire/ -- Spectros, developer and manufacturer of advanced molecular sensing and imaging devices which shed light on life-threatening diseases, announced today that it has signed exclusive distribution deals for both its T-Stat® VLS Tissue Oximeter and Sensors. The markets covered include Australia, New Zealand, The Netherlands, Belgium, Luxembourg (Benelux), Suriname, Italy, France, Spain, Portugal, Poland, Greece, Turkey, and Russia. The values of the deals were not disclosed.

Founded in 1995, Spectros develops tissue oximeters and sensors for various uses with applications in critical care, gastroenterology, colon-rectal surgery, plastic surgery, and vascular surgery. T-Stat® VLS Tissue Oximeter is an FDA-approved and CE Marking device approved for neonatal, pediatric, and adult use.

"We are proud to be working with our new partners, Endovations in Australia, Fysicon Medical Technology in the Netherlands, and A.M.I. Italia s.r.l. in Italy, who are providing the T-Stat® franchise in their respective markets in order to realize our potential," said David Benaron, CEO of Spectros. "Support of our technology is a testament to their commitment to offering their healthcare communities with innovative and life-saving solutions," commented Robert Kum, director of commercial development.

The T-Stat® franchise includes the T-Stat® VLS Tissue Oximeter, utilizing Visible Light Spectroscopy (VLS), a multi-wavelength, noninvasive, continuous, real-time monitor of absolute hemoglobin oxygen saturation. The T-Stat® Sensors allow for ischemia monitoring in various applications, including critical care (neonatal, pediatric, and adult), gastroenterology (G.I. ischemia diagnosis), colon-rectal surgery (anastomosis), plastic surgery (free flaps), and vascular surgery (AAA, TAAA, and EVAR).

Based in Australia, Endovations Pty. Ltd. is a leader in the field of critical care, respiratory, anesthesia, and surgical applications. Endovations will distributor the T-Stat® VLS Tissue Oximeter and Sensors to the Australian and New Zealand markets.

Based in the Netherlands, Fysicon Medical Technology is a leader in the field of cardiology. The company will distribute the T-Stat® VLS Tissue Oximeter and Sensors to the Dutch, Belgium, and Luxembourgian (Benelux), and Suriname markets.

Based in Italy, A.M.I. Italia s.r.l. is a leader in the patient monitoring market. A.M.I. will distribute the T-Stat® VLS Tissue Oximeter and Sensors in Italy, France, Spain, Portugal, Poland, Greece, Turkey, and Russia.

About Spectros

Spectros markets advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's lead product, the T-Stat Tissue Oximeter, was the first medical device FDA approved as sensitive to ischemia, an insufficient blood flow to tissue. T-Stat is the only commercially available tissue oximeter that utilizes state-of-the-art visible light spectroscopy (VLS) technology. In clinical use, T-Stat is a real-time, absolute, non-invasive, and continuous tissue monitor that analyzes 260 wavelengths of light, far more than the 2-4 wavelengths used in other monitors for superior accuracy. Spectros is also developing molecular diagnostic tools for breast and prostate cancer currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally. For further information, contact Elizabeth van Thillo, Marketing, Spectros Corporation, at info@spectros.com or 650/529.2865

SOURCE Spectros


'/>"/>
SOURCE Spectros
Copyright©2009 PR Newswire.
All rights reserved

Related biology news :

1. Europes number 1 scientific network signs off with launch of new report
2. Kings College London signs agreement to strengthen Brazilian research links
3. New DNA test uses nanotechnology to find early signs of cancer
4. University has grand designs to build a house of straw
5. Web-based program designs more efficient farm terrace layouts
6. WARF signs license agreement with Pfizer for human embryonic stem cells
7. Unifying the animate and the inanimate designs of nature
8. Ben-Gurion University of the Negev signs collaborative contract with Bayer CropScience
9. UK robot sub searches for signs of melting 60 km into an Antarctic ice shelf cavity
10. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
11. Engineering technology pinpoints earliest signs of animal life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... , Feb. 7, 2017 The biometrics ... by the confluence of organizations, desires to better ... knowledge-based systems (password and challenge questions), biometrics is ... government systems. The market is driven by use ... between consumer and enterprise uses cases, with consumer-facing ...
(Date:2/7/2017)... February 7, 2017 Ipsidy Inc. ... Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a provider ... processing services, is pleased to announce the following changes ... Effective January 31, 2017, Philip D. Beck ... CEO and President.  An experienced payment industry professional and ...
(Date:2/2/2017)... Fla. , Feb. 2, 2017   ... a clinical-stage immuno-oncology company specializing in the development ... for the treatment of cancer and metastatic disease, ... scale-up and GMP manufacturing of a second clinical ... vaccine targeting folate receptor alpha. The manufactured vaccine ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... oncology and dermatology biopharmaceutical company, today is providing ... its previously announced rights offering of up to ... stock and Series C Convertible Preferred Stock to ... As previously announced, the rights offering ...
(Date:2/24/2017)... ... 24, 2017 , ... FireflySci, Inc is an explosive small business that continues ... goal of bringing their powerful cuvette and spectrophotometer calibration to the spectroscopy ... is going on as they add yet another mark on the global map. , ...
(Date:2/23/2017)... RAFAEL, Calif., Feb. 23, 2017 ... U.S. dollars, except per share data, unaudited)Three Months Ended ... ChangeTotal BioMarin Revenue $   ...   22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... 2017  Seattle,s upscale Capitol Hill neighborhood, with its swanky shops, ... a head lice treatment salon to set up shop. But ... and a French bistro on E Madison Ave, and CEO ... any old lice clinic, we pride ourselves on being a ... some of the stigma associated with lice. Everyone can get ...
Breaking Biology Technology: